Faculty

Needs Statement

This set of training modules is intended for school personnel training (nurses and designated, non-licensed staff) who will provide diabetes-related care and medication administration to students with diabetes in a school setting. Speakers include diabetes educators, nurses, and care providers with expertise in the field of pediatric diabetes from UKHC Barnstable Brown Diabetes Center, Wendy Novak Diabetes Institute (Louisville), and Cincinnati Children's Diabetes Center.

Module 4 addresses various diabetes-related technology, including the use of continuous glucose monitors (CGM) and continuous subcutaneous insulin infusion (CSII) therapy.

Target Audience

Nurses and other designated non-licensed school personnel

Objectives

Upon completion of this activity, participants will be able to:

• Review basics of basal-bolus insulin therapy and blood glucose monitoring.
• Introduce Smart Pen and benefits
• Discuss Continuous Glucose Monitoring - Brands, Benefits, and Best Practices
• Define Continuous Subcutaneous Insulin Infusion (CSII) therapy - Brands, Benefits, and Best Practices
• Provide considerations for use in a school setting

 

Accreditation

In support of improving patient care, University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Other
UK Healthcare CECentral certifies this activity for 1.00 hour of participation.

Faculty Disclosure

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months.  An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

None of the planners, faculty, and others in control of educational content for this educational activity have a relevant financial relationship(s) to disclose with ineligible companies.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include a discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation

Acknowledgement

In collaboration with UK College of Nursing Continuing Education Office.